Shares of EDGE MEDICAL-B (02675) have plummeted more than 18%, reaching a new low of HK$41.7 during the session. At the time of writing, the stock was down 18.71% to HK$41.7, with a turnover of HK$96.98 million.

The decline comes as the Shanghai and Shenzhen stock exchanges announced an adjustment to the list of securities eligible for the Southbound Stock Connect program. EDGE MEDICAL-B has been added to this list, with the change taking effect from June 8.

In a previous research report, DBS noted that the company is expected to achieve breakeven by 2026, driven by the key advantages of its core product, the MP1000. The bank highlighted overseas markets as the primary growth driver for EDGE MEDICAL-B, which has currently obtained registration approvals in 55 countries and regions. However, the report cautioned that global geopolitical tensions could potentially slow the company's market penetration.